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MortalityBackground: The beneﬁts of CRT for symptomatic heart failure (HF) patients with a wide QRS and reduced left
ventricular ejection fraction (LVEF ≤35%), are well established .Post-hoc subgroup analyses suggest that CRT
beneﬁt may extend to patients with LVEF N35%.
Methods: The MIRACLE EF was a prospective, randomized, controlled, double-blinded study to evaluate
CRT-P in NYHA II–III HF patients with LBBB and with LVEF of 36%–50% and no previous pacing or ICD.
The primary endpoint was a composite of time to ﬁrst HF event or death. All patients were implanted
with a CRT-P and randomized 2:1 to CRT-P ON or CRT-P OFF groups. The minimum follow up time was
24 months.
Results: The MIRACLE EF study was stopped for enrollment futility after 13 months and enrolling only 44
patients. The main difﬁculties in recruiting patients were lack of eligible patients, previous ICD implants,
and the reluctance of institutions, patients or physicians to enroll in the study which included a potential
5 year CRT OFF period.
Conclusion: Despite a careful design, identiﬁcation and randomization of eligible patients were challeng-
ing and a trial to assess morbidity and mortality trial was not feasible. The MIRACLE EF experience illus-
trates the difﬁculties of designing a scientiﬁcally robust but feasible study to assess potential new
indications for implantable devices. Smaller randomized studies with surrogate endpoints may therefore
be more reasonable, although the potential impact of such studies on clinical practice, guidelines, and
reimbursement remain to be determined.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The beneﬁts of Cardiac Resynchronization Therapy (CRT) have been
ﬁrmly established in heart failure (HF) patients who remain in New
York Heart Association (NYHA) Classes II–III despite optimal medicalarolinskaUniversity Hospital, S-
land Ltd. This is an open access articltherapy and have a wide QRS and reduced left ventricular ejection frac-
tion (LVEF) (≤35%) [1–6]. Subgroup analyses suggest that the beneﬁts
are larger in patients with wider QRS durations and/or left bundle
branch block (LBBB) [7–9] and this has been recognized in current
guidelines [10,11]. Recently, it has been suggested that CRT may also
be beneﬁcial in patients LVEF N35% [12–14] by results of post hoc
subgroup analysis from the PROSPECT [12], MADIT-CRT [13], and
REVERSE [14] trials. Patients with NYHA II–III HF with LVEF 36–50% re-
main at high risk ofmortality/morbidity, but have few established treat-
ments, and their prognosis is worse in the presence of bundle branche under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
350 C. Linde et al. / International Journal of Cardiology 202 (2016) 349–355block [15,16]. Therefore, the aimof theMIRACLE EF studywas to test the
hypothesis that CRT prolongs time to death or HF event in patients with
NYHA Classes II–III HF, LVEF of 36–50%, and LBBB. This paper describes
the process of creating the study protocol, the inﬂuence of the U.S.
Food andDrug Administration (FDA) on trial design, challenges in effec-
tively recruiting patients, and lessons learned.
2. Methods
MIRACLEEF aimed to evaluate CRT pacemaker (CRT-P) devices in symptomaticHF pa-
tients with LVEF 36–50% and to compare CRT-P ON to optimalmedical therapy alone CRT-
POFF over at least 24months of post-implant follow-up.We hypothesized that CRTwould
improve the combination of morbidity and mortality, improve health-related Quality of
Life (QoL), and reduce healthcare costs. The study was expected to require approximately
2900 enrolled patients in order to reach approximately 2300 implanted subjects, across up
to 275 centers in theUS, Canada, Europe, Asia, Africa, Latin America, Australia and theMid-
dle East.
2.1. Study design
The MIRACLE EF study was a prospective, randomized, controlled, double-blinded,
global multi-center, cardiac resynchronization therapy (CRT) in heart failure (HF) clinical
study. Inclusion and exclusion criteria are listed in Table 1. At baseline, eligibility was to be
veriﬁed. All patients with LVEF 36–40% were required to be on optimal HF medication in-
cluding beta-blockers and ACE-inhibitors or angiotensin II receptor-blockers with orTable 1
Inclusion and exclusion criteria in the MIRACLE EF study.
Inclusion criteria
Chronic heart failure N90 days in duration
LVEF between 36% to 50%
LBBB with QRS ≥130 ms
Patient is either
A. NYHA Class III OR
B. NYHA Class II, with hospitalization for HF in the last 12 months OR
C. NYHA Class II, without hospitalization for HF, but with BNP ≥250 pg/ml or
NT-proBNP N1000 pg/ml
Sinus rhythm at time of enrollment
Sinus rhythm at time of enrollment
Optimal medical therapy per guidelines for Heart Failure, Ischemic Heart Disease
(IHD), Hypertension and Atrial Fibrillation, as applicable
No change in non-diuretic heart failure medical therapy within prior 30 days
Able to receive pectoral implant
Able to receive pectoral implant
Signed and dated informed consent
Expected to remain available for follow-up visits
Willing and able to comply with the Clinical Investigation Plan
Exclusion criteria
Requires permanent cardiac pacing
Indicated for implantable cardioverter deﬁbrillator (ICD)
CRT-P, pacemaker, ICD or CRT-D device implanted previously or currently
Mechanical tricuspid heart valve
Unstable angina or an acute MI within past 40 days
Coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI)
within the past 90 days
Chronic (permanent) atrial arrhythmias
Cardioversion for atrial ﬁbrillation within the past 30 days
Primary valvular disease, indicated for valve repair or replacement.
Treatable pericardial constraint
Restrictive (inﬁltrative) cardiomyopathies, such as amyloidosis, sarcoidosis, or
hemochromatosis or other restrictive, hypertrophic, or reversible
cardiomyopathy
Enrolled in a concurrent study, with exception of an approved observational study
(e.g. registries)
Life expectancy of less than 24 months due to non-cardiac conditions
b18 years of age
Female patient who is pregnant, or of childbearing potential and not on a reliable
form of birth control
Heart transplant, or is currently on a heart transplant list
Signiﬁcant renal dysfunction, (serum creatinine level N2.5 mg/dl or ≥275 μmol/L or
estimated glomerular ﬁltration rate (eGFR) ≤30 mL/min/1.73 m2)
Signiﬁcant hepatic dysfunction (hepatic function panel (serum) N 3 times upper
limit of normal)
Chronic or treatment-resistant severe anemia (hemoglobin b10.0 g/dL)
Patient is on intravenous inotropic drug therapywithout aldosterone-antagonists on stable doses for at least one month. For patients
with LVEF N40%, where evidence and guideline recommendations for use of neuro-
hormonal antagonist therapy as treatments for HF is lacking, optimal medical therapy
depended on co-morbidity such as ischemic heart disease, hypertension, diabetes or atrial
ﬁbrillation.
Subjectsmeeting all eligibility criteriawouldundergo a CRT-P implant. All successfully
implanted patientswould be randomized to CRT-PONor CRT-POFF in a 2:1 ratio and then
remain in their randomized assignment for at least 24 months and up to 60 months or
until the study was stopped. An enrollment rate of 0.33 patients/center/month was esti-
mated based on average performance in previous CRT studies. Stopping rules deﬁned en-
rollment futility as a recruitment b0.1/center/month in at least 30 centers over 6 months.
2.2. Study procedures and data collection
Potentially eligible study subjects were to be screened within 30 days of signing in-
formed consent to establish eligibility and collect baseline data. Subjects were then im-
planted within 14 days of enrollment and randomized within 14 days of successful
implant. Following successful implant, subjects were randomized in a 2:1 ratio to either
CRT-P ON or CRT-P OFF. For patients programmed to CRT OFF, the device was conserva-
tively programmed to provide anti-bradycardia right ventricular pacing if spontaneous
heart rate was below 40 bpm. Comprehensive follow-up visits would occur at 6 and 24
months, while limited follow-upwould occur at 1, 3, 12, 18, 30, and every 6months there-
after up until 60 months (Fig. 1, Table 2). Data collected at baseline included an echocar-
diogram, BNP or NT proBNP, 12-lead ECG, physical examination, 6 minute hall walk,
quality of life (QOL), medical history and cardiovascular (CV) medications. QOL was
assessed by the Kansas City Cardiomyopathy Questionnaire [18] and EuroQol [19] and
the latter was used to perform the Health Economic analysis. Data collected at follow-
ups included an echocardiogram, 12-lead ECG, BNP or NT proBNP, quality of life, CVmed-
ications, device evaluation, NYHA class. System modiﬁcations, adverse events and health
care utilizations were collected as they occurred throughout the study. All study subjects
were to be followed to a common study closing date after the pre-speciﬁed number of
events had occurred, or the trial was stopped.
NYHA class was determined by a blinded heart failure specialist or nurse while the
electro-physiologists un-blinded to therapy allocation checked the device. There were
core labs for both ECG and echocardiography. The ECG core lab veriﬁed the presence of
LBBB and prolonged QRS duration. An Echocardiographic Core Lab determined the LVEF
and left ventricular end systolic volume (LVESV) measures at baseline and during
follow-up, these measurements were used in determining whether a subject experienced
secondary endpoints such as worsening systolic function after 6 and 24 months. The
24 month evaluation was chosen since it was anticipated from previous trials that the
maximal extent of reverse remodeling would have been reached within that time and
then sustained [17]. The LVEF for inclusion was based on the investigational center's as-
sessment to mimic what would happen in normal practice after the trial. The echo core
lab tested the proﬁciency of the center sonographer prior to their activation on the study.
2.3. Study objectives
The primary efﬁcacy endpoint of MIRACLE EF was a composite endpoint similar to
other CRT studies in HF patients (CARE-HF [3], MADIT-CRT [5], RAFT [6]) and drug studies
in HF such as the EMPHASIS-HF study [20] and would assess time to ﬁrst event. The
composite endpoint consisted of all-cause mortality or a HF event, deﬁned as either an
in-patient hospitalization for HF, or an outpatient event requiring invasive clinical inter-
vention and management for HF (i.e. IV diuretics, ultraﬁltration, or equivalent) and
overnight stay. The classiﬁcation of all HF events was to be adjudicated by a blinded End-
point Adjudication Committee (EAC) of qualiﬁed clinicians.
The primary safety endpoint of MIRACLE EF was freedom from system-related com-
plications of greater than 80% in randomized subjects as of 6months post implant to dem-
onstrate the safety of CRT-P devices in this population.
The six secondary endpoints were: (1) mortality, (2) secondary composite objective,
(3) recurrent HF events, (4) QoL, (5) healthcare system cost effectiveness and (6) changes
in LVEF and LVESV. Mortality, a component of the primary endpoint, would be assessed
separately for comparison between the study groups.
The secondary composite endpoint would include the following components: all-
cause mortality, HF event, deﬁned as either an in-patient hospitalization for HF, or an out-
patient event requiring invasive clinical intervention and management for HF (i.e. IV di-
uretics, ultraﬁltration, or equivalent) and overnight stay, or worsening systolic function
meeting an ICD/CRT-D indication, deﬁned as a drop in LVEF to 35% or below, with an ab-
solute decrease of ≥10% after maximum tolerated doses of guideline HF medications had
been established.
Itwas anticipated that subjectswhose systolic functionworsened during the course of
the study might experience a drop in LVEF to 35% or below resulting in an ICD or CRT-D
indication, as well as an increased risk of morbidity and mortality. These events were
therefore, included in the secondary composite endpoint. The determination of worsening
LVEF meeting an ICD indication would be made using a standard of care echocardiogram
initiated by a blinded clinician because of clinical worsening or as deemed necessary for
management of the subject. The LVEF would then be adjudicated by the Echo Core Lab
and the EAC would then adjudicate for inclusion as a study endpoint, including review
of medications to conﬁrm all requirements. Use of LVEF changes in the endpoint could
not be determined using the protocol-deﬁned echo data (at 6 and 24 months), unless
Fig. 1. Study design and ﬂow diagram.
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team to un-blind echo results for that subject.
Recurrent HF eventswould be compared between the study groups and be tracked by
the recording of admission and discharge dates for both inpatient hospitalizations and
outpatient events that required overnight stay, and were determined by adjudication
from the EAC. QOLwould be compared between the study groups by two validated instru-
ments, the EQ-5D and the Kansas City Cardiomyopathy Questionnaire, with changes from
baseline assessed through 24 months. Healthcare system cost-effectiveness of CRT-P
would be evaluated through the use of standard and accepted economicmethods. Mortal-
ity, healthcare utilization and the utility index from the EQ-5Dwould be used in this eval-
uation. LVEF and LVESV would be assessed at baseline, 6 months and 24 months and a
comparison of the longitudinal changes between treatment groups was to be made.
Progression of HF in the control group was hypothesized, including worsening of LVEF.Table 2
Data collection overview.
Study requirement Baseline CRT-P
implant
PHD⁎ Wound
check
3 mont
Patient informed consent X
Inclusion/exclusion assessment X
Physical exam X X
Echo X⁎⁎
12-lead ECG X⁎⁎
Blood tests X⁎⁎
BNP or NT-proBNP X⁎⁎
CV medications X X
Medical history X
Device check X X X X
Randomization X
NYHA assessment X⁎⁎ X
6-minute hall walk X
Quality of life and utility
measures (KCCQ and EQ-5D)
X X
Blinding assessment
LV lead implant assessment X
Telephone contact
CRT-P cardiac resynchronization therapy pacemaker, CV= cardiovascular, Echo= echocardiog
sociation Functional Class, KCCQ = Kansas City Cardiomyopathy Questionnaire [18]LV = left v
⁎ Pre-hospital discharge visit.
⁎⁎ Unless done within 30 days prior to enrollment.In previous CRT studies, reverse remodeling was observed by measuring changes in the
non-paced LVEF at follow-up.
2.4. Sample size calculation
The estimated mortality rate was calculated from the CHARM study which included
patients with similar disease states [21]. TheMIRACLE EF studywas event driven, compar-
ing the hazard rate ofﬁrst events from the composite primary efﬁcacy endpoint. The num-
ber of required events was estimated in order to observe statistical signiﬁcance with an
assumed hazard ratio of 0.75 or less. Four interim analyses were pre-speciﬁed, and the
sample size requirement assumed a type I error rate of 0.039 based on the nominal
value derived from an O'Brien-Fleming alpha spending function and a power of 0.9 for
the ﬁnal analysis. Based on published analyses [21], it was projected that the primaryhs 6 months 12 and 18
months
24 months 30, 36, 42, 48, 54
and 60 months
66, 72, 78
months, etc.
X X X X
X X
X X
X X
X X X X
X X X X
X X X X
X X
X X X
X
X
raphy, EuroQoL, European Quality of Life Questionnaire [19], NYHA=NewYork Heart As-
entricular, PHD = pre hospital discharge.
Fig. 2.Patients screened for participation in the study and the reasons for their ineligibility.
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subjects per year. The sample size calculations further assumed a hazard ratio of 0.75 be-
fore cross-over, a loss-to-follow-up rate of 2% per year, a total cross-over rate between
study arms of 15% (with one half contributing to the primary endpoint prior to cross-
over), three years of enrollment and a minimum of two years of follow-up. The allocation
of study arm would be according to a 2:1 randomization schedule. Under these assump-
tions, 609 events would be observed in approximately 2300 randomized subjects over
the length of the study.
3. Results
The MIRACLE EF steering committee was assembled in 2011 to re-
view the literature, assemble available information, and subsequently
draft a proposed protocol. Followingdiscussionwith the FDAaddressing
details of the study protocol including their recommendation of a
double-blinded design or a robust blinded endpoint, the MIRACLE EF
protocol received an Investigational Device Exemption (IDE) from the
FDA on November 1, 2012. The ﬁrst subject was enrolled on January 3,
2013. On February 18, 2014, the study was stopped due to enrollment
futility. At that time, 72 active clinical study sites from 5 countries had
enrolled 44 subjects and randomized a total of 26 subjects. All 26 sub-
jects had received CRT-P implants and were alive at the time of study
closure. Management of CRT-P devices in these implanted patients
after study exit was left to the discretion of their attending study physi-
cian. None of the implanted devices were explanted before study close.
The MIRACLE EF study sought to enroll a new population of patients
for CRT therapy.While this has been a challenge tomany clinical studies
of new indications, the majority of the active sites in MIRACLE EF had
previous experience enrolling new indication device trials, and yet
N50 of these sites failed to enroll even one eligible subject. The
MIRACLE EF trial was burdened with two major challenges to enroll-
ment: 1) identiﬁcation of eligible patients; and 2) patient and clinician
acceptance of the long-term double-blinded design requiring a non-
indicated implantable device in the control arm.
3.1. Patient identiﬁcation
Based on available national HF registries, we estimated that 4–5% of
HF patients have both LBBB and an EF 35–50%, compared to 10–13% of
HF patients with LVEF b35% [10,11]. However, screening of databases
or ﬁle screening within high-volume HF centers participating in the
study did not reach these expectations. Many otherwise eligible pa-
tients alreadywere implantedwith primary prevention ICDs. Moreover,
many of the patients successfully screened for the MIRACLE EF study
were determined ineligible based on the baseline procedures, meaning
that patients' records did not contain the information necessary to de-
termine eligibility (Fig. 2). Twenty ﬁve study centers reported screening
a total of 60,372 patients toﬁnd5754potentially eligible patients for the
study to enroll 44 and randomize 26 patients. The most common rea-
sons for not being eligible for the study were the following: absence of
LBBB (35%), QRS too narrow (15%), ongoing device therapy (16%;
most often an ICD), or NYHA II HF without prior hospitalization or
with low BNP or NT proBNP (14%). This observation is consistent with
the IMPROVE HF registry, which showed that for each patient with an
LVEF b35% identiﬁed through chart review to be eligible for CRT, more
than four others with LVEF b35% were indeterminate because of miss-
ing information, such as the QRS duration or NYHA class [22].
3.2. Patient, investigator and institution acceptance
A randomized, double-blinded study was proposed for two main
reasons: (1) optimal medical therapy for HF is required under current
indications for CRT, and is required in CRT studies to demonstrate ben-
eﬁt over standard of care. However, themajority of patients in the study
population (LVEF N40%) do not have HF medication recommendations
in the current guidelines [23,24]. We believed that an unblinded trial
would introduce too great a risk of selective medication management,potentially creating bias in the primary outcome. Study endpoints
were expected to be primarily HF interventions, where knowledge of
the treatment group assignment could impact decision-making.
Using a blinded trial design required an evaluation of the study risks
and beneﬁts to participants. A blinded trial meant exposing control arm
patients to the risks of surgical intervention. Based on an analysis of the
results from the REVERSE and the MIRACLE trials, the six month risk of
system-related complications is approximately 15%. This risk is juxta-
posed with the potential beneﬁts to the patient population should the
MIRACLE EF trial have successfully demonstrated efﬁcacy. Given the
risks of hospitalization and death observed in this population in the
CHARM study, themorbidity andmortality were considered potentially
signiﬁcant enough to offset the risk of device implantation. Further, be-
cause the statistical design was event-driven, not all study subjects
would need to be followed for ﬁve years and required follow-up could
be as low as 24 months before devices in the control arm could be re-
programmed to pacing.
Unfortunately, some investigators and subjects declined to partici-
pate because the double-blinded parallel design required a surgical in-
tervention with a potentially long follow-up with only back up pacing
in the control group (Fig. 2). At the time the study was stopped there
were 72 Ethics committee's approvals out of 90 submissions, 35 of
which had required a 2nd submission, 4 rejections and 14 applications
still in process.4. Discussion
Wewanted to test the hypothesis that CRT-P would be beneﬁcial in
HF patients with LVEF 36–50% for the combined endpoint of mortality
353C. Linde et al. / International Journal of Cardiology 202 (2016) 349–355and HF hospitalizations since these patients have high mortality and
morbidity, especially in the presence of left bundle branch block.
The most important ﬁnding from theMIRACLE EF study was the dif-
ﬁculty in ﬁnding study patients fulﬁlling the inclusion criteria. Themain
reasons were 1) number of eligible patients for the study was far less
than anticipated from the literature, especially regarding LBBB; 2) insti-
tutions, investigators and patients were reluctant to participate in a
study that contained a ﬁve year inactive randomization arm (CRT-
OFF); or 3) eligible patients already had an ICD, whichwas an exclusion
criteria.
The LVEF criterion for CRT indications in current guidelines [10,
11] is an LVEF of 30% [5,6] or 35% [1–4] based on previous CRT stud-
ies. Such patients also have an indication for an ICD. In contrast, HF
patients with LVEF N40% are not indicated for primary prevention
ICDs or CRTs and also lack indications for evidence-based HFmedica-
tions [23,24]. LVEF is recognized as a risk predictor for morbidity and
mortality in HF patients [21,25]. While the risk of hospitalization
and/or death declines as LVEF increases, an LVEF in the range of
36% to 45% still confers a signiﬁcant risk of adverse outcomes, where-
as a higher LVEF does not further contribute to mortality [21,25].
Moreover, while the proportion of HF patients with reduced ejection
fraction has decreased, that of HF patients with relatively preserved
LVEF has increased, probably due to better management of acute
myocardial infarctions and an aging population [26]. Taken together,
these facts illustrate the need for therapies in this increasing popula-
tion with mildly reduced LVEF.
In the CHARM studies performed nearly 10 years ago, the risk of
death and hospitalizations was still high in patients with LVEF N40%
and even greater in the presence of LBBB [16]. Data from the Swedish
National Heart failure Registry [15] based on 25,171 patients indicate
that 25% of HF patients with LVEF 40–45% had wide QRS ≥120 ms, and
wide QRS was linked to a greater mortality risk independently of
LVEF. We assumed that LBBB would be encountered in about 4–5% of
NYHA II–III HF and LVEF 36–50%.
Results of post-hoc analyses of randomized controlled trials of CRT
reported comparable CRT beneﬁts in patients with an LVEF N35%
[12–14] as in patients with LVEF ≤35%. In a sub-study from the
PROSPECT [12] trial that included NYHA III–IV HF patients, Chung
et al. reported similar beneﬁts from CRT regarding the clinical compos-
ite response by Packer and reverse remodeling in patients with LVEF
N35% compared to those with LVEF b35%.
In the MADIT CRT trial with NYHA I–II patients, 38% had a baseline
LVEF above the inclusion criteria of LVEF ≤30% when evaluated by the
echocardiographic-core-lab [13]. In these patients there was a signiﬁ-
cant reduction in risk for HF hospitalizations or death compared to ICD
alone. Moreover, the patients with LVEF N30% experienced greater ex-
tent of reverse remodeling than subjects with lower EF. Similar results
were obtained in the REVERSE study [14] in which blinded echo core
lab analysis revealed that almost 24% patients had LVEF N30%. After a
24 month follow-up time, CRT in patients with LVEF N30% resulted in
a signiﬁcant 74% relative risk reduction in time to HF hospitalizations
or death compared to 42% in the group with LVEF ≤30%. There were
also modest reductions in LV end systolic volume index and LV mass
in LVEF N30% patients although not to the same extent as in those
with LVEF b30%. We therefore, designed the MIRACLE EF trial to pro-
spectively study CRT effects in HF patients with LBBB and LVEF in the
range 36–50%, to potentially establish new treatment in this under-
served population. There are many lessons learned from the MIRACLE
EF experience.
4.1. Study design
The steering committee initially planned a CRT arm compared to op-
timal medical therapy (OMT) alone since patients in this study lacked
an indication for a device. FDA questioned this design due to lack of
blinding. The double-blinded, parallel design with an implantedcontrol-arm programmed to CRT OFF may be more scientiﬁcally rigor-
ous, but the consequence proved unappealing to patients, who declined
the prospect of a CRT-P implant programmed OFF except for anti-
bradycardia pacing for up to ﬁve years. It is our belief that patients' will-
ingness to participate would have been greater with a control arm of
OMT with no device. Understandably, the risks of surgery without the
beneﬁts of therapy (even an ICD)were not embraced bymany patients,
and some clinicians managing eligible patients, as well as some Institu-
tional Review Boards andMedical Ethics Committees. In theMADIT CRT
[5] and RAFT [6] studies, the patients in the control group received an
ICD. Since MIRACLE EF study patients did not fulﬁll an indication for a
primary prevention ICD we could not provide such a control arm.
4.2. Placebo effects
Placebo effects are powerful in device studies [27] andmay exagger-
ate or mimic treatment effects. Improvements may also be related to
improved baseline care,ﬂuid and nutritional guidance and better adher-
ence to medical therapy. In a recent meta-analysis of 150 consecutive
CRT studies the incremental symptomatic response to CRT was only
16% [28]when calculated as deducting the placebo effects in the control
arm from the treatment effects in the CRT arm. It has also been sug-
gested that a controlled studywith a shamproceduremay be particular-
ly justiﬁed in device studies focusing on a patient group with no
guideline indicated therapy [29] such as the Miracle EF study popula-
tion. We therefore believed it was justiﬁed to plan to subject our pa-
tients to CRT implantation and with randomization to CRT ON or OFF
in order to separate a therapy effect from placebo in a new HF popula-
tion. Moreover, patients were randomized 2:1 CRT ON versus CRT OFF
to increase the probability of receiving therapy and patients assigned
to CRT OFF would have been offered to be programmed to CRT ON
once a beneﬁt had been established.
Previous trials have used non-implanted control arms to demon-
strate CRT efﬁcacy, including CARE HF [3] and COMPANION [30]. More
recently, however, it has been suggested that studies with only objec-
tive endpoints such as mortality [31] or changes in echocardiographic
parameters may not need an inactive control arm but this reasoning
to our knowledge has not yet been applied in device studies.
4.3. Study duration
In the MIRACLE study, the use of surrogate endpoints including
change in Six Minute Hall-walk, quality of life, and NYHA class
allowed for a short-duration of follow-up (6-months) with cross-
over. More recent CRT trials, such as REVERSE [4], MADIT-CRT [5]
and RAFT [6], were conducted in HF populations already indicated
for other rhythm device therapy. Lessons from these trials are that
the milder disease states (NYHA II) demanded much longer observa-
tion times to provemortality beneﬁts. RAFTwas the only one of these
trials with a long enough observation time of 40 months to demon-
strate a mortality beneﬁt by CRT compared to control [6]. The
MIRACLE EF study planned to include both NYHA II–III patients
with an anticipated low event rate both regarding mortality and HF
morbidity. Therefore, a long study follow up timewas required to ob-
serve a sufﬁcient number of events.
At the time of study closure, the MIRACLE EF Steering Committee
could not reconcile the theoretical equipoise based on the scientiﬁc lit-
erature with the reality of the situation within the clinical and patient
community. Our experience of designing and running the study raises
important points for the choice of endpoints in future device studies
with populations not already indicated for devices. Today, the common-
ly used endpoint for HF trials is the combination of HF hospitalization
andmortality [20] or the combination of HFhospitalization and CVmor-
tality [32]. In a population with decreasing event rates due to improve-
ments in HF and other cardiovascular medication and invasive
treatments it may prove extremely hard to calculate an accurate event
354 C. Linde et al. / International Journal of Cardiology 202 (2016) 349–355rate in a long term RCT study. Therefore introduction of additional end-
points — more upstream in HF pathophysiology — such as reverse re-
modeling (in the study group) or adverse remodeling [4] in the
control group [33] have been introduced. An alternative is to choose re-
verse remodeling as primary endpoint or to power the study for reverse
remodeling. REVERSE [4] did not reach its primary endpoint of percent
worsening in the control arm by the clinical composite endpoint [33]
but did reach the powered secondary of drop in LV end-systolic volume
index. If the CCSwouldhave been used in the commonway [34] i.e. with
its entire distribution of scores, the REVERSE study would have reached
its primary endpoint, as in previous CRT studies such as the MIRACLE
ICD [35]. Although considered a surrogate endpoint, reverse remodeling
is linked to improved morbidity and mortality both in device [36,37]
and drug studies [31]. Gold et al. recently reported that signiﬁcant re-
verse remodeling by CRT at 6 months in REVERSE was associated with
a 68% mortality reduction [36]. Similar observations were made in
RCTs on HF medication such as most recently with ivabradine in the
SHIFT trial [32]. In recentmeta-analysis comprising 30mortality studies,
25drug/device therapies and 88 remodeling trials short term LV remod-
eling were associated with lower mortality [37] with more pronounced
mortality effects among patients with greater reductions in left ventric-
ular volumes. Importantly, theMADIT_ASIA trial thatwas also terminat-
ed early due to poor enrollment did have reverse remodeling as its
primary endpoint [38].4.4. Study population
MIRACLE EF initially targeted patients with LVEF in the range 36–
50% and wide QRS. Broadly, this group would have better survival and
lower morbidity than patients already indicated for CRT and would
have been expected to contain a larger proportion of women. So, a sub-
group with greater potential for beneﬁt was selected. All subjects were
required to have LBBB, and also must have either NYHA Class III symp-
toms or NYHA Class II with additional risk-factor(s). LBBB is linked to
greater beneﬁt by CRT in substudies [7–9] and registry studies [39].
This higher-risk group was selected to promote detecting a beneﬁt
and to demonstrate cost-effective use of CRT in a reasonable sample
size and follow-up duration
The electronic medical record (EMR) has become standard in
many countries. EMR was to be considered a valuable tool for both
the identiﬁcation of potential subjects for study outside existing in-
dications if they may be used for such a purpose by patient privacy
reasons. To have the possibility to search for HF patients with LBBB
and LVEF 36–50% would have been helpful for recruitment in
MIRACLE EF. However, it was not possible to perform such search
in most hospitals by patient privacy reasons or for operational rea-
sons with the EMRs.
For future studies such issues may determine recruitment success
since patients may be outside of in-hospital Cardiology units and seen
by private cardiologists, internists or general practitioners who do not
refer patients to heart failure specialists or to physicians implanting
CRT and would be even less likely to do so in milder disease states.
Pre-trial feasibility assessments may reduce the risk of subsequent
early closure of studies due to enrollment futility. Nonetheless, we be-
lieve that the major reason for not ﬁnding patients for the MIRACLE EF
was not solely such technical difﬁculties but might also have been due
to the low number of patients fulﬁlling inclusion criteria, in particular
LBBB, than anticipated and the poor patient and physician acceptance
of the study design. In a recent registry of patients with HF with pre-
served LVEF (deﬁned as LVEF N45%) [40] LBBB was only found in 3.5
%. Among our screened patients it was even lower. It is clear that we
overestimated the presence of LBBB in our study emphasizing that the
true prevalence of LBBB in our LVEF HF range remains unknown. Future
trials would need to account for different referral patterns and preva-
lence of HF with LVEF 36–50%, as well as investigate the distributionof QRS widths and prevalence of co-existing LBBB in these patients, in
order to optimize the trial design.
4.5. Lessons for the future
The fact remains that heart failure patients with electrical
dyssynchrony and less severe LV dysfunction may beneﬁt from CRT.
Our experience demonstrates that although scientiﬁcally justiﬁable, a
large mortality and morbidity study with double blinding with a long
randomized follow up time of therapy turned OFF is unlikely to be fea-
sible. A smaller parallel randomized study (CRT or no device) with re-
verse LV remodeling as the primary endpoint appears more realistic.
Potentially it can be accompanied by a long term follow up comparing
the mortality with that expected by the use of a predictive model. One
suchmodel, theMAGGIC [41], is based on established independent pre-
dictors of mortality. The MAGGIC meta-analysis included individual
data on 39,372 patients with HF, both reduced and preserved left ven-
tricular ejection fraction (EF), from 30 cohort studies, six of which
were clinical trials. It remains to be seen if such meta-analysis and use
of predictive models will inﬂuence clinical practice, practice guidelines,
and reimbursement strategies.
5. Conclusion
TheMIRACLE EF trial raises questions of how to study new therapies
in HF patients. These include choice of study population and primary
endpoints. Themorewemove into lower risk HFpopulations the harder
it will be to demonstrate morbidity andmortality improvements on top
of existingmedical therapy. Since the greater life-long beneﬁts are to be
found with preventive rather than therapeutic approaches, the ideal
study design for such therapy remains to be established. The difﬁculties
of implementing scientiﬁcally robust long-term studies in lower risk
populations are substantial, and further discussions between trialists,
regulators, patients, industry and physicians are essential:more reliance
may be required on surrogate endpoints or on a combination of the clin-
ical composite endpoint with surrogate endpoints followed by registry-
type long term up.
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